As with children studies, Supernus ADHD drug shows fast onset of action in adolescents

Positive pivotal data on Supernus’ $SUPN ADHD drug in children gave investors pause earlier this month because of the lack of dose response at the higher 400 mg dose, which weighed on the shares. On Thursday, the drug developer followed up with largely similar Phase III data from an adolescent study, but the drug’s swift onset of action, as seen in previous trials with children, may be a key differentiator from existing ADHD non-stimulant medications.